CCL3 and CCL4 (MP1-α and MP1-β, respectively) and CCL5 chemokines are increased in brains of AD subjects (Tripathy et al., 2010), suggesting that pharmacological inhibition of the P2X7 receptor could decrease this pro-inflammatory effect during AD pathology. Here, CCL4 is linked to Alzheimer disease.